论文信息 - The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry. - 字舞流文

The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry.

A. Iagnocco | B. Ogunjimi | A. Tomelleri | L. Dagna | S. Tharwat | P. Sfikakis | V. Caggiano | F. Ciccia | R. Giacomelli | S. Monti | M. Govoni | E. Bartoloni | A. Vitale | H. Direskeneli | Claudia Fabiani | G. Emmi | G. Lopalco | B. Frediani | F. Iannone | D. Rigante | L. Cantarini | F. Cardinale | E. Bizzi | O. Viapiana | P. Ruscitti | F. Carubbi | P. Cipriani | M. Tektonidou | R. C. Kardaş | Ilenia Riccucci | G. Ragab | P. Sfriso | J. Torres-Ruiz | L. Fotis | G. Sebastiani | A. Balistreri | K. Laskari | J. Hernández-Rodríguez | K. Jahnz-Różyk | G. Conti | M. Hussein | A. Gidaro | N. Khalil | M. Maggio | I. Mormile | Ş. Erten | E. Więsik-Szewczyk | A. Karamanakos | M. Frassi | D. Iacono | F. Alibaz-Oner | J. Makowska | C. Gaggiano | F. La Torre | J. Sota | A. Olivieri | A. Tufan | E. Giudice | I. Almaghlouth | E. Bellis | O. Brzezińska | A. L. Gullo | E. Martín-Nares | K. Asfina | F. Ruffilli | M. Tarsia | A. Maier | F. Riccio | Verónica Gómez-Caverzaschi | Riccardo Lubrano | I. D. Cola | H. A. M. Giardini | D. Opriș-Belinski | M. Morrone | Marília Ambuel D'Agostin | Isabelle Parente de Brito Antonelli | Luca Navarrini | R. Lubrano | Gaafar Ragab | H. Giardini | Ewa Więsik-Szewczyk

[1] C. Campochiaro,et al. Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry , 2022, Frontiers in Medicine.

[2] P. Ruscitti,et al. Perspectives on the use of non-biological pharmacotherapy for adult-onset Still’s disease , 2022, Expert opinion on pharmacotherapy.

[3] P. Sfikakis,et al. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry. , 2022, Seminars in arthritis and rheumatism.

[4] K. Onel,et al. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives , 2022, Annals of medicine.

[5] R. Giacomelli,et al. The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. , 2022, Seminars in immunology.

[6] J. Baker,et al. Treatment of early rheumatoid arthritis: Methotrexate and beyond. , 2022, Current opinion in pharmacology.

[7] B. Ogunjimi,et al. Development and Implementation of the AIDA International Registry for Patients With Still's Disease , 2022, Frontiers in Medicine.

[8] P. Ferguson,et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis , 2022, Arthritis & rheumatology.

[9] A. Iagnocco,et al. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still’s disease , 2022, Rheumatology.

[10] I. Durieu,et al. Detection and Prediction of Macrophage Activation Syndrome in Still’s Disease , 2021, Journal of clinical medicine.

[11] Hsin-Hua Chen,et al. The effectiveness of tocilizumab in treating refractory adult-onset Still’s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response , 2021, Clinical Rheumatology.

[12] P. Hur,et al. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. , 2021, Seminars in arthritis and rheumatism.

[13] F. Atzeni,et al. Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification. , 2021, Rheumatology.

[14] A. Vitale,et al. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease , 2020, Mediators of inflammation.

[15] A. Iagnocco,et al. Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences , 2020, Annals of the Rheumatic Diseases.

[16] F. Atzeni,et al. Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients , 2020, Arthritis Research & Therapy.

[17] R. De Giorgio,et al. The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of observational studies , 2020, Therapeutic advances in musculoskeletal disease.

[18] R. Giacomelli,et al. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy , 2020, Expert review of clinical pharmacology.

[19] C. Campochiaro,et al. The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. , 2020, Clinical and experimental rheumatology.

[20] G. Cavalli,et al. Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes , 2020, Frontiers in Medicine.

[21] T. Aune,et al. Methotrexate and its mechanisms of action in inflammatory arthritis , 2020, Nature Reviews Rheumatology.

[22] Mark M. Davis,et al. Emergent high fatality lung disease in systemic juvenile arthritis , 2019, medRxiv.

[23] G. Cavalli,et al. Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response , 2019, Front. Pharmacol..

[24] N. Wulffraat,et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus , 2018, The Journal of Rheumatology.

[25] E. Feist,et al. Mechanisms, biomarkers and targets for adult-onset Still’s disease , 2018, Nature Reviews Rheumatology.

[26] Y. Shoenfeld,et al. A comprehensive review on adult onset Still's disease. , 2018, Journal of autoimmunity.

[27] R. Schneider,et al. Systemic Juvenile Idiopathic Arthritis. , 2018, Pediatric clinics of North America.

[28] G. Valentini,et al. Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort , 2018, The Journal of Rheumatology.

[29] K. Amano,et al. Era of steroid sparing in the management of immune-mediated inflammatory diseases , 2018, Immunological medicine.

[30] S. Raychaudhuri,et al. Review: Genetics and the Classification of Arthritis in Adults and Children , 2018, Arthritis & rheumatology.

[31] G. De Sarro,et al. Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies , 2017, Expert review of clinical immunology.

[32] M. Valenti,et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers , 2016, BMC Medicine.

[33] M. Kawano,et al. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. , 2016, Clinical immunology.

[34] D. Solmaz,et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. , 2016, Journal of autoimmunity.

[35] M. González-Gay,et al. Adult-onset Still's disease: Advances in the treatment. , 2016, Best practice & research. Clinical rheumatology.

[36] A. Brachat,et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity , 2015, Pediatric Rheumatology.

[37] F. Martinon,et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart , 2014, Immunologic Research.

[38] R. Giacomelli,et al. Methotrexate: an old new drug in autoimmune disease , 2014, Expert review of clinical immunology.

[39] P. Nigrovic. Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis? , 2014, Arthritis & rheumatology.

[40] M. Schiller,et al. Clinical Manifestations but not Cytokine Profiles Differentiate Adult-onset Still’s Disease and Sepsis , 2010, The Journal of Rheumatology.

[41] E. Baldissera,et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. , 2010, Arthritis and rheumatism.

[42] A. Bakkaloğlu,et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis , 2006, Clinical Rheumatology.

[43] M. Suarez‐Almazor,et al. International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[44] J. Piette,et al. Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease , 2002, Medicine.

[45] O. Meyer,et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. , 1999, The Journal of rheumatology.

[46] M. Akizuki,et al. Preliminary criteria for classification of adult Still's disease. , 1992, The Journal of rheumatology.

[47] J. Esdaile,et al. Adult Still's Disease: Manifestations, Disease Course, and Outcome in 62 Patients , 1991, Medicine.

[48] L. Cooperstein,et al. Adult-onset Still's disease. Clinical course and outcome. , 1987, Arthritis and rheumatism.

[49] Chang-Keun Lee,et al. Clinical features and prognosis in 82 patients with adult-onset Still's disease. , 2014, Clinical and experimental rheumatology.